Cure My Disease

Don't miss your cure!

 Log in / Sign up

Keytruda after chemo shows promise in Hard-to-Treat ovarian cancer

NCT ID NCT03430700

Completed Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) could help keep cancer from growing in people with platinum-resistant ovarian, fallopian tube, or peritoneal cancer. After initial chemotherapy with paclitaxel, 20 participants received pembrolizumab as maintenance therapy. The study aimed to see if this approach could extend the time without cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pembrolizumab (Keytruda)
What this could lead to
If successful, this could point toward a new maintenance therapy to delay cancer progression in platinum-resistant ovarian cancer.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The drug may not extend progression-free survival significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube carcinoma fallopian tube neoplasm ovarian cancer ovarian carcinoma peritoneum cancer primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CANCER OVARIAN CANCER PERITONEAL CANCER

Contacts and locations

Locations

  • Barts

    London, United Kingdom

  • Churchill Hospital

    Oxford, United Kingdom

  • Imperial

    London, United Kingdom

  • UCLH

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.